Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Series A Non-Voting Convertible Preferred Stock	Series A Non-Voting Convertible Preferred Stock Preferred Stock	Series B Non-Voting Convertible Preferred Stock	Series B Non-Voting Convertible Preferred Stock Preferred Stock
Beginning balance (in shares) at Dec. 31, 2023									150,000
Beginning balance at Dec. 31, 2023									$ 84,555
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)									122,000
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs									$ 168,850
Ending balance (in shares) at Mar. 31, 2024									272,000
Ending balance at Mar. 31, 2024									$ 253,405
Beginning balance, preferred stock (in shares) at Dec. 31, 2023							437,000		0
Beginning balance at Dec. 31, 2023	$ 184,016	$ 10	$ 763,191	$ 302	$ (764,414)		$ 184,927		$ 0
Beginning balance, common stock (in shares) at Dec. 31, 2023		36,057,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		572,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	4,390		4,390
Stock-based compensation expense	8,385		8,385
Foreign currency translation adjustment	16			16
Unrealized gain (loss) on marketable securities	(681)			(681)
Net loss	(43,857)				(43,857)
Ending balance, preferred stock (in shares) at Mar. 31, 2024							437,000		0
Ending balance at Mar. 31, 2024	152,269	$ 10	775,966	(363)	(808,271)		$ 184,927		$ 0
Ending balance, common stock (in shares) at Mar. 31, 2024		36,629,000
Beginning balance (in shares) at Dec. 31, 2023									150,000
Beginning balance at Dec. 31, 2023									$ 84,555
Ending balance (in shares) at Sep. 30, 2024									0
Ending balance at Sep. 30, 2024									$ 0
Beginning balance, preferred stock (in shares) at Dec. 31, 2023							437,000		0
Beginning balance at Dec. 31, 2023	184,016	$ 10	763,191	302	(764,414)		$ 184,927		$ 0
Beginning balance, common stock (in shares) at Dec. 31, 2023		36,057,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation adjustment	37
Unrealized gain (loss) on marketable securities	1,118
Net loss	(151,722)					$ (36,733)		$ (9,105)
Ending balance, preferred stock (in shares) at Sep. 30, 2024							346,000		17,000
Ending balance at Sep. 30, 2024	327,390	$ 12	1,086,237	1,457	(916,136)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Sep. 30, 2024		51,396,000
Beginning balance (in shares) at Mar. 31, 2024									272,000
Beginning balance at Mar. 31, 2024									$ 253,405
Increase (Decrease) in Temporary Equity [Roll Forward]
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock (in shares)									(272,000)
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock									$ (253,405)
Ending balance (in shares) at Jun. 30, 2024									0
Ending balance at Jun. 30, 2024									$ 0
Beginning balance, preferred stock (in shares) at Mar. 31, 2024							437,000		0
Beginning balance at Mar. 31, 2024	152,269	$ 10	775,966	(363)	(808,271)		$ 184,927		$ 0
Beginning balance, common stock (in shares) at Mar. 31, 2024		36,629,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock (in shares)									272,000
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock	253,405								$ 253,405
Conversion of Series B non-voting convertible preferred stock into common stock (in shares)		10,198,000							(255,000)
Conversion of Series B non-voting convertible preferred stock into common stock	0	$ 1	244,009						$ (244,010)
Exchange of Series A non-voting convertible preferred stock into common stock (in shares)		3,640,000					(91,000)
Exchange of Series A non-voting convertible preferred stock for common stock	0	$ 1	38,501				$ (38,502)
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)		250,000
Issuance of common stock in connection with exercise of pre-funded warrants	1		1
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		66,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	494		494
Stock-based compensation expense	7,243		7,243
Foreign currency translation adjustment	4			4
Unrealized gain (loss) on marketable securities	(194)			(194)
Net loss	(38,837)				(38,837)
Ending balance, preferred stock (in shares) at Jun. 30, 2024							346,000		17,000
Ending balance at Jun. 30, 2024	374,385	$ 12	1,066,214	(553)	(847,108)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Jun. 30, 2024		50,783,000
Ending balance (in shares) at Sep. 30, 2024									0
Ending balance at Sep. 30, 2024									$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with at-the-market offerings, net of offering costs (in shares)		426,000
Issuance of common stock in connection with at-the-market offerings, net of offering costs	11,750		11,750
Vesting of restricted stock units (in shares)		34,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		153,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	1,318		1,318
Stock-based compensation expense	6,955		6,955
Foreign currency translation adjustment	17			17
Unrealized gain (loss) on marketable securities	1,993			1,993
Net loss	(69,028)			0	(69,028)	$ (14,610)		$ (704)
Ending balance, preferred stock (in shares) at Sep. 30, 2024							346,000		17,000
Ending balance at Sep. 30, 2024	327,390	$ 12	1,086,237	1,457	(916,136)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Sep. 30, 2024		51,396,000
Beginning balance, preferred stock (in shares) at Dec. 31, 2024						346,045	346,000	16,667	17,000
Beginning balance at Dec. 31, 2024	$ 517,804	$ 13	1,334,223	180	(972,432)		$ 146,425		$ 9,395
Beginning balance, common stock (in shares) at Dec. 31, 2024	60,257,023	60,257,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		19,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	$ 218		218
Stock-based compensation expense	8,859		8,859
Foreign currency translation adjustment	14			14
Unrealized gain (loss) on marketable securities	488			488
Net loss	(44,773)				(44,773)
Ending balance, preferred stock (in shares) at Mar. 31, 2025							346,000		17,000
Ending balance at Mar. 31, 2025	482,610	$ 13	1,343,300	682	(1,017,205)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Mar. 31, 2025		60,276,000
Beginning balance, preferred stock (in shares) at Dec. 31, 2024						346,045	346,000	16,667	17,000
Beginning balance at Dec. 31, 2024	$ 517,804	$ 13	1,334,223	180	(972,432)		$ 146,425		$ 9,395
Beginning balance, common stock (in shares) at Dec. 31, 2024	60,257,023	60,257,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation adjustment	$ (22)
Unrealized gain (loss) on marketable securities	633
Net loss	(92,673)					$ (17,138)		$ (825)
Ending balance, preferred stock (in shares) at Sep. 30, 2025						346,045	346,000	16,667	17,000
Ending balance at Sep. 30, 2025	$ 455,100	$ 13	1,363,581	791	(1,065,105)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Sep. 30, 2025	60,471,793	60,472,000
Beginning balance, preferred stock (in shares) at Mar. 31, 2025							346,000		17,000
Beginning balance at Mar. 31, 2025	$ 482,610	$ 13	1,343,300	682	(1,017,205)		$ 146,425		$ 9,395
Beginning balance, common stock (in shares) at Mar. 31, 2025		60,276,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		97,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	730		730
Stock-based compensation expense	9,378		9,378
Foreign currency translation adjustment	(36)			(36)
Unrealized gain (loss) on marketable securities	(192)			(192)
Net loss	(36,717)				(36,717)
Ending balance, preferred stock (in shares) at Jun. 30, 2025							346,000		17,000
Ending balance at Jun. 30, 2025	455,773	$ 13	1,353,408	454	(1,053,922)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Jun. 30, 2025		60,373,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock units (in shares)		34,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)		65,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	607		607
Stock-based compensation expense	9,566		9,566
Foreign currency translation adjustment	0
Unrealized gain (loss) on marketable securities	337			337
Net loss	(11,183)				(11,183)	$ (2,066)		$ (100)
Ending balance, preferred stock (in shares) at Sep. 30, 2025						346,045	346,000	16,667	17,000
Ending balance at Sep. 30, 2025	$ 455,100	$ 13	$ 1,363,581	$ 791	$ (1,065,105)		$ 146,425		$ 9,395
Ending balance, common stock (in shares) at Sep. 30, 2025	60,471,793	60,472,000